Novel treatments for acute myeloid leukemia #FIMM_UH
Helsinki, Finland
Joined October 2021
- Tweets16
- Following101
- Followers81
- Likes71
Kontro Lab retweeted
This paper reports that authors identify molecular patterns linked to primary resistance to VEN–HMA therapy, including a higher BCL‑XL/BCL‑2 ratio and frequent TP53 mutations. These findings point to potential therapeutic strategies worth exploring
Read more in depth 👉bit.ly/3Lllpo9
Kontro Lab retweeted
Data presented at #ESMO25 by Dr Mika Kontro on the Macrophage reprogrammer #bexmarilimab plus azacitidine in myelodysplastic syndrome (BEXMAB)
@myESMO @OncoAlert @Daver_Leukemia @Dr_AmerZeidan
Kontro Lab retweeted
1/4
Capillary Sampling Enables Venetoclax Concentration Measurement in Acute Myeloid Leukaemia Within Academic Multicentre Trial
New study by @LabKontro and colleagues – study highlights 👇
Kontro Lab retweeted
Drug sensitivity testing on leukemia cells can predict how patients with acute myeloid leukemia (AML) will respond to a new combination therapy.
New @LabKontro results allow treatments to be tailored to those who are most likely to benefit.
📰@HUS_fi:
hus.fi/en/newsroom/drug-sens…
ALT Tanja Ruokoranta, Ida Vänttinen and Mika Kontro working in a cell culture room wearing white laboratory coats. Photo: Ville Männikkö/HUS
Kontro Lab retweeted
Leukemiasolujen lääkeherkkyystestauksella voidaan ennustaa akuuttia myelooista leukemiaa sairastavien potilaiden hoitovaste uudelle lääkeyhdistelmälle.
@LabKontro tulokset mahdollistavat hoidon kohdentamisen siitä eniten hyötyville potilaille.
📰@HUS_fi: hus.fi/ajankohtaista/laakehe…
ALT Tutkijat Tanja Ruokoranta, Ida Vänttinen ja Mika Kontro työskentelemassä soluviljelylaboratoriossa valkoiset takit päällä. Kuva: Ville Männikkö / HUS
Kontro Lab retweeted
Meet our K. Albin Johansson Cancer Researcher @hkuusanm. Heikki has a versatile background in translational laboratory studies and focuses now on novel treatments for acute myeloid leukemia in @LabKontro. Read more 👇syopainstituutti.com/researc…
Kontro Lab retweeted
A clinical trial performed in Finland has shown that a drug sensitivity test performed on patient's own cells in laboratory conditions predicts patient's response to a new effective leukemia drug, venetoclax. The study was led by Mika Kontro & @hkuusanm.
helsinki.fi/en/hilife-helsin…
Kontro Lab retweeted
1/ Excited to share our study with @ollidufva suggesting venetoclax resistance and BCL-XL dependence in erythroid/megakaryoblastic AML @BloodJournal
doi.org/10.1182/blood.202101…
Kontro Lab retweeted
Ex vivo venetoclax sensitivity predicts responses in both de novo and s/R/R AML patients @LabKontro #ASH22
